Fidelity Advisor® Biotechnology Z (FIJYX)

28.82 +0.44  +1.55% Jan 28 USD
View Full Chart
Total Returns Chart

Key Stats

Net Asset Value 28.82
Turnover Ratio 62.00%
1 Year Fund Level Flows -534.36M

Performance & Returns

  Total Return Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M -3.42% -1.70% 89
3M 12.00% 13.06% 73
6M 12.86% 10.13% 44
YTD -2.90% -1.20% 91
1Y 14.21% 15.71% 80
3Y -- 14.50% --
5Y -- 7.44% --
10Y -- 14.57% --
15Y -- 11.12% --
20Y -- 9.52% --
As of Jan. 28, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 0.91% 0.91% 0.00%
Stock 98.55% 98.55% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.53% 0.53% 0.00%
As of Nov. 30, 2019

Region Exposure

Americas 96.07%
North America 96.07%
Latin America 0.00%
Greater Europe 2.94%
United Kingdom 0.00%
Europe Developed 2.94%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.99%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.99%
Market Classification
% Developed Markets 99.01%
% Emerging Markets 0.99%
As of Nov. 30, 2019. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Nov. 30, 2019

Stock Market Capitalization

Giant 31.59%
Large 22.49%
Medium 25.09%
Small 17.78%
Micro 3.04%
As of Nov. 30, 2019

Stock Style Exposure

Large Cap Value 22.79%
Large Cap Blend 23.77%
Large Cap Growth 11.98%
Mid Cap Value 0.00%
Mid Cap Blend 0.00%
Mid Cap Growth 24.12%
Small Cap Value 0.21%
Small Cap Blend 4.38%
Small Cap Growth 12.75%
As of Nov. 30, 2019
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
ABBV AbbVie Inc 17.94% 83.22 -0.66%
AMGN Amgen Inc 12.33% 227.42 +1.15%
VRTX Vertex Pharmaceuticals Inc 10.61% 232.88 +0.39%
ALXN Alexion Pharmaceuticals Inc 8.14% 107.41 +0.41%
NBIX Neurocrine Biosciences Inc 3.51% 103.63 +2.01%
ALNY Alnylam Pharmaceuticals Inc 2.91% 118.18 +3.02%
ASND Ascendis Pharma A/S ADR 2.51% 136.13 +0.11%
ARGX argenx SE ADR 2.34% 147.92 +3.02%
FGEN FibroGen Inc 2.32% 42.08 +0.36%
GILD Gilead Sciences Inc 2.25% 64.31 -0.08%
As of Nov. 30, 2019
Advertisement

Basic Info

Investment Strategy
The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments. The fund is non-diversified.
General
Security Type Mutual Fund
Oldest Share Symbol FBTIX
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Health
Fund Owner Firm Name Fidelity Investments
Benchmark Index
S&P 500 TR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Eirene Kontopoulos 1.46 yrs

Share Classes

Symbol Share Class
FBTAX A
FBTCX C
FBTIX Inst
FBTTX M

Net Fund Flows

1M -27.56M
3M -151.36M
6M -304.63M
YTD -534.36M
1Y -534.36M
3Y -1.104B
5Y -273.32M
10Y 1.175B
As of Dec. 31, 2019

Risk Info

Beta (5Y) --
Historical Sharpe Ratio (10Y) --
Historical Sortino (All) 2.190
Daily Value at Risk (VaR) 1% (All) 3.52%
Monthly Value at Risk (VaR) 1% (All) 10.72%

Fundamentals

Dividend Yield TTM (1-28-20) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 22.66
Weighted Average Price to Sales Ratio 7.715
Weighted Average Price to Book Ratio 5.901
Weighted Median ROE 3.31%
Weighted Median ROA -7.03%
Forecasted Dividend Yield 1.54%
Forecasted PE Ratio 14.60
Forecasted Price to Sales Ratio 5.511
Forecasted Price to Book Ratio 4.581
Number of Holdings 68
As of Nov. 30, 2019

Growth Estimates

Forecasted 5 Yr Earnings Growth 10.46%
Forecasted Book Value Growth 6.66%
Forecasted Cash Flow Growth 26.30%
Forecasted Earnings Growth 22.22%
Forecasted Revenue Growth 12.82%
As of Nov. 30, 2019

Comparables

Edit

Attributes

Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment 0.00 USD
Minimum Subsequent Investment 0.00 USD
Fees
Actual 12B-1 Fee --
Actual Management Fee 0.54%
Administration Fee --
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
Key Dates
Inception Date 10/2/2018
Termination Date
Last Annual Report Date 7/31/2019
Last Prospectus Date 9/28/2019
Attributes
Exchange Traded Share No
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.